RPS6

Across TCGA pan-cancer cohorts, RPS6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPS6 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RPS6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS6 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

SKCM, PAAD, and LUSC are the cancer types where RPS6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	IV	0.415	0.861	.014	15	view →
PAAD	OS	Median	II,III,IV	0.205	0.556	.002	12	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	12	view →
BLCA	DFS	Median	All	0.836	0.606	.045	2	view →
UCEC	DFS	Median	All	0.951	0.617	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPS6–SKCM (OS)

Open the SKCM breakdown →